ACM
AVTX icon

Asymmetry Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Asymmetry Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-186
Closed -$1.17M – 26
2021
Q3 		$1.17M Buy
+186
New +$1.51M 0.7% 25

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Asymmetry Capital Management's AVTX Position: Q4 2021 in Review

Asymmetry Capital Management sold out of Avalo Therapeutics (AVTX) in Q4 2021, closing a stake of 186 shares — an estimated $1.17M sold.

Asymmetry Capital Management first reported a position in AVTX in Q3 2021 and held it in 1 quarter. The position peaked at $1.17M in Q3 2021. 70 funds tracked by Wall St. Rank hold AVTX as of Q4 2021.

  • Asymmetry Capital Management reported no remaining Avalo Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 186 Avalo Therapeutics shares in Q4 2021, an estimated $1.17M.
  • Asymmetry Capital Management first reported a position in Avalo Therapeutics in Q3 2021 and held it in 1 quarter.
  • Asymmetry Capital Management's Avalo Therapeutics position peaked at $1.17M in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.